AVELUMAB COMBINED WITH REGORAFENIB IN SOLID TUMORS WITH TERTIARY LYMPHOID STRUCTURES: A PHASE 2 REGOMUNE TRIAL COHORT

1Sophie Cousin, 1Carine Bellera, 2Jean-Philippe Guégan, 3Jean-Philippe Metges, 4Antoine Adenis, 5Rastislav Bahleda, 6Philippe Cassier, 7Coralie Cantarel, 1Michèle Kind, 1Jean Palusser, 1Lucile Vanhersecke, 1Alban Bessede, 2Antoine Italiano*. 1Institut Bergonié, Bordeaux, France; 2Exploïte Immuno-Oncology, Bordeaux, Girond, France; 3Hopital Augustin Morvan, Brest, France; 4Institut du Cancer de Montpellier, Montpellier, France; 5Centre Leon Berard, Lyon, France; 6Exploïte, Bordeaux, France

Background Mature tertiary lymphoid structures (mTLS) predict improved outcome in patients treated with immune checkpoint inhibitors (ICIs).1–3 However, a significant proportion of patients with TLS-positive tumors do not respond to ICI when used as a single agent and may therefore benefit from combination therapy. The multikinase inhibitor, regorafenib, deplete regulatory T cells, an immune population associated with resistance to ICI in TLS-positive tumors.4 We report the results of the PD-L1 inhibitor avelumab combined with regorafenib in patients with mTLS-positive advanced solid tumors.

Methods ‘Regomune’ is an open-label, multicenter phase II study assessing the combination of avelumab (10mg/kg IV every 14 days) with regorafenib (160 mg daily for 3 weeks in a 4-week cycle) in patients with advanced mTLS-positive solid tumors. The mTLS status was centrally assessed as previously described.1 5 All patients had confirmed progressive disease at inclusion, based on a central review of imaging. The primary efficacy endpoint was a 6-month non-progression rate using RECIST v1.1 based on blinded central review. 29 assessable patients were deemed necessary, and to meet the primary end-point, at least 8 patients needed to be progression-free at 6 months.

Results Between January 2021 and July 2022, 132 patients (5 centers) underwent mTLS screening. Of these, 55 (41.7%) were identified as mTLS+, and 38 were included in the study. The top five histological subtypes were MSS colorectal cancer (15.8%), sarcoma (13.1%), oesogastic (10.5%), biliary tract (7.9%), and pancreatic cancer (7.9%). The most frequent grade 3/4 adverse events were palmar-plantar erythrodysesthesia syndrome (23.7%), maculo-papular rash (18.4%), fatigue, and oral mucositis (7.9%) each. No treatment-related deaths were reported. Of the 34 patients assessed for efficacy, 16 (47%) showed tumor shrinkage, with 9 achieving a partial response (26.7%) and 7 having stable disease (20.6%). The primary endpoint achievement.

Conclusions This is the pioneering histology-agnostic clinical trial employing mTLS as a biomarker for patient selection for treatment with an immune checkpoint inhibitor-based regimen. Durable responses were recorded, even in cases typically resistant to immunotherapy. Additional data from tumor and blood samples will be presented during the meeting.

Trial Registration NCT03475953

REFERENCES

Ethics Approval The REGOMINE study obtained ANSM and ethics approval (CPP Sud-Ouest Bordeaux) as per European Regulation. All participants gave informed consent before taking part.

http://dx.doi.org/10.1136/jitc-2023-SITC2023.1519

A1744